HRT for Menopause – Flashcards

Unlock all answers in this set

Unlock answers
question
Why do we care about menopause?
answer
The symptoms are bothersome for our patients
question
Symptoms of menopause
answer
*Vasomotor symptoms* Irregular menses Episodic amenorrhea Sleep disturbances Mood swings *Vaginal dryness* Depression
question
What are examples of vasomotor symptoms?
answer
Hot flashes Night sweats
question
FSH and menopause
answer
An elevated FSH level may indicate a woman is experiencing menopause FSH > 30 mIU/mL
question
Non Pharm Therapy for hot flashes
answer
Smoking cessation Limit alcohol and caffeine Limit hot beverages (e.g., coffee/tea, soups) Limit spicy foods Keep cool, and dress in layers Stress reduction (e.g., meditation, relaxation exercises) Increase exercise Paced respiration
question
How long should non pharm therapy be used for hot flashes?
answer
3 months
question
What's the big deal about about HRT?
answer
Go to therapy for years Most effective treatment option for alleviating moderate and severe vasomotor and vaginal symptoms
question
US Preventive Services Task Force
answer
Not all post menopausal women should be prescribed HRT Individualized based on risk factors
question
Heart and Estrogen/Progestin Replacement Study (HERS)
answer
Women with established CHD were at an increased risk of experiencing a myocardial infarction within the first year of HT HT should not be recommended for the secondary prevention of CHD
question
Women's Health Initiative (WHI)
answer
Increase the risk in women with underlying CHD risk factors. Increase Risk of breast cancer was also increased after a woman was on combination estrogen and progestogen for approximately 3 years *Should not be initiated or continued for the primary prevention of CHD*
question
Follow Up: WHI
answer
Published data 10 years ago HT has complex pattern of risk and benefits Combination therapy associated with more of increased risks (e.g., myocardial infarction, stroke, deep vein thrombosis, breast cancer, gallbladder disease) (Caused many clinicians and patients to stop using hormone therapy)
question
WHI: Overall
answer
Landmark trial enrolled few women younger than 60 years and few women who were within 10 years of menopause onset
question
Menopause Treatment Guidelines
answer
2017 Hormone Therapy Position Statement of The North American Menopause Society Considered WHI but also balanced this data with newer information from other randomized controlled trials enrolling younger women
question
General Statements in Guidelines
answer
1. Hormone therapy is the most effective treatment for VMS and GSM and has been shown to prevent bone loss and fracture. 2. *Benefits are most likely to outweigh risks for symptomatic women who initiate HT when aged younger than 60 years or who are within 10 years of menopause onset.* 3. Hormone therapy should be individualized 4. The risks of HT in the WHI and other studies differ overall for Estrogen Therapy and Estrogen-Progestogen Therapy, with a *more favorable safety profile for Estrogen Therapy* 5. *Practitioners should use:* 6. Assessment of risk for estrogen-sensitive cancers, bone loss, heart disease, stroke, and VTE is appropriate when counseling menopausal women 7. Decision making about HT should be incorporated into a broader discussion of lifestyle modification to manage symptoms and risks for chronic diseases of aging.
question
How do the guidelines suggest therapy should be individualized?
answer
Indication(s) or evidence-based treatment goals Woman's age and/or time since menopause in relation to initiation or continuation, Woman's personal health risks and preferences, Balance of potential benefits and risks of HT versus nonhormone therapies or options
question
What do the guidelines suggest practitioners should use?
answer
Appropriate HT type, dose, formulation, route of administration Appropriate duration of use to meet treatment objectives Periodic reassessment of changes in a woman's health, and anticipated benefits, risks, and treatment goals over time.
question
What are the risks of HRT?
answer
CHD Stroke VTE Breast cancer Endometrial cancer Ovarian cancer Lung cancer Gallbladder and Liver
question
CHD Studies with HRT
answer
Reduced risk of CHD in women who initiate HT when aged younger than 60 years and/or who are within 10 years of menopause onset In women who initiate HT more than 10 years from menopause onset, and clearly by 20 years, there is potential for increased risk of CHD The WHI found that both CEE alone and CEE with MPA increased risk of CHD, with potentially greater risk with CEE and MPA, which was significant when initiated in women who were more than 20 years from menopause onset
question
Stroke and HRT
answer
No increased risk of stroke in women aged younger than 60 years or who were within 10 years of menopause onset Increased risk of stroke in women who initiate HT when aged older than 60 years and/or who are more than 10 years from menopause onset Lower-dose oral as well as lower-dose transdermal therapy has less effect on risk of stroke, although RCT data are lacking.
question
VTE and HRT
answer
Increased risk of VTE w/ oral CEE alone and CEE w/ MPA therapy (highest risk in first 1 - 2 years) For women who initiated HT when aged younger than 60 years, the absolute risk of VTE was rare but significantly increased Higher absolute risks of VTE (with risk of PE) in women initiating HT more than10 years from menopause onset Transdermal HT as well as lower doses of oral or transdermal HT have less effect on risk of VTE There is no evidence of increased risk of VTE with low dose vaginal ET used for genitourinary symptoms
question
HRT and Breast Cancer
answer
Nonsignificant reduced risk of breast cancer with CEE alone in women with a hysterectomy A rare absolute risk of breast cancer (; 1 additional case/1,000 person-years of use) was seen with daily continuous-combined CEE and MPA in the WHI Duration of HT use may be an important factor in breast cancer risk, because in some studies, risk increased with longer durations of use. Different HT regimens may be associated with increased breast density Breast tenderness, breast density, and breast cancers were not increased with oral CEE plus bazedoxifene compared with placebo. HT use does not further increase risk of breast cancer in women with a family history of breast cancer or in women after oophorectomy for BRCA 1 or 2 gene mutation.
question
HRT and Endometrial Cancer
answer
Unopposed systemic ET in postmenopausal women with an intact uterus increases the risk of endometrial cancer, which is dose and duration related More risk is seen earlier with higher doses and persisting for several years after discontinuation. *Adequate concomitant progestogen is recommended for women with an intact uterus when using systemic ET.*
question
HRT and Ovarian Cancer
answer
If an association between HT and ovarian cancer exists, the absolute risk is likely to be rare and more likely with longer durations Limited observational data have not found an increased risk of ovarian cancer in women with a family history or a BRCA mutation who use EPT.
question
HRT and Lung Cancer
answer
There appears to be an overall neutral effect of HT on lung cancer incidence. Smoking cessation should be encouraged, with increased surveillance for older smokers, including current or past users of HT.
question
HRT and Gallbladder and Liver
answer
Risk of gallstones, cholecystitis, and cholecystectomy is increased with oral estrogen-alone and combination HT Observational studies report lower risk with transdermal HT than with oral and with oral estradiol compared with CEE, but neither observation is confirmed in RCTs
question
Steps for HRT Selection
answer
1. Determine indication/goal of therapy 2. Determine if patient is interested in HRT Therapy 3. Determine if patient has any contraindication to HRT Therapy 4. Determine Appropriate HT type, dose, formulation, route of administration, duration
question
HRT FDA Approved Indications
answer
Vasomotor symptoms Prevention of bone loss Hypoestrogenism Genitourinary syndrome of menopause/Vulvovaginal atrophy
question
Vasomotor symptoms and HRT
answer
Hormone therapy is recommended as first-line therapy for bothersome VMS in women without contraindications
question
Prevention of bone loss and HRT
answer
Hormone therapy may be considered as a primary therapy for prevention of bone loss and fracture in postmenopausal women at elevated risk of osteoporosis or fractures, primarily for women aged younger than 60 years or who are within 10 years of menopause onset.
question
Hypoestrogenism and HRT
answer
For women with hypoestrogenism caused by hypogonadism, POI, or premature surgical menopause without contraindications, HT is recommended until at least the median age of menopause (52 y)
question
Genitourinary syndrome of menopause/Vulvovaginal atrophy
answer
When isolated genitourinary symptoms caused by menopause are present, low-dose vaginal ET is recommended over systemic ET as first-line medical therapy
question
What are alternatives to HRT?
answer
SSRIs SNRIs Gabapentin Clonidine Soy Protein OTC
question
What SSRIs can be used in menopause?
answer
Fluoxetine Citalopram Paroxetine Sertraline
question
What SNRI can be used in menopause?
answer
Venlafaxine
question
Soy protein should not be used in what patients?
answer
Those with a history of estrogen dependent cancers
question
What are absolute contraindications of systemic hormone therapy?
answer
Undiagnosed abnormal genital bleeding Known, suspected, or history of cancer of the breast Known or suspected estrogen- or progesterone-dependent neoplasia Active deep vein thrombosis, pulmonary embolism, or a history of these conditions Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) Liver dysfunction or disease
question
Who are considered to not be good candidates for systemic hormone therapy?
answer
Women more than 10 years past menopause
question
What are relative contraindications of systemic hormone therapy?
answer
Elevated blood pressure Hypertriglyceridemia Impaired liver function and past history of cholestatic jaundice Hypothyroidism Fluid retention Severe hypocalcemia Ovarian cancer Exacerbation of endometriosis Exacerbation of asthma Diabetes mellitus, migraine, systemic lupus erythematosus, epilepsy, porphyria, and hepatic hemangioma
question
Who is a candidate for hormone replacement therapy?
answer
No self history of breast cancer CVD risk ; 10% No contraindications
question
Considerations if HRT is for endometrial protection
answer
For women with a uterus if using systemic estrogen: - Endometrial protection requires an adequate dose and duration of a progestogen or use of the combination CEE with bazedoxifene - Progestogen therapy is not recommended with low-dose vaginal Estrogen Therapy, but appropriate evaluation of the endometrium should be performed if vaginal bleeding occurs, given the limits of safety data.
question
Lowering doses or hanging to transdermal HT
answer
May be appropriate as women age or in those with metabolic syndromes (hyperTG with a risk of pancreatitis or fatty liver)
question
Transdermal are better for what women?
answer
Obese Have DM or metabolic syndrom
question
Metabolic syndrome criteria
answer
3 or more of the following: - Abdominal obesity (waist circumference ; 35 inches - TG ;150 mg/dL - High Density Lipoproten 130/85 mmHG - Fasting Glucose ;110 mg/dL
question
How do you feel about compounded bioidentical HT?
answer
Should be avoided!
question
Safety concerns with bioidentical HT
answer
Possibility of overdosing or underdosing, lack of efficacy and safety studies, and lack of a label providing risks.
question
What should you do if compounded bioidentical HT is prescribed?
answer
Concerns about safety should be discussed Indication for prescribing compounded rather than government approved bioidentical HT should be documented (allergy, medical need for lower-than-available dose, different preparation).
question
Duration of HRT Women starting menopause early (before 40)
answer
Continued use at least until the median age of menopause (52) is recommended
question
Observational studies in early menopausal women
answer
Benefits outweigh the risks for effects on bone, heart, cognition, GSM, sexual function, and mood
question
Duration of HRT Estrogen Progesterone Therapy
answer
Increase duration has potential of increased (rare) risk of breast cancer
question
Duration of HRT Start of HRT
answer
Reduced risk: if started in women aged younger than 60 years or within 10 years of menopause onset Greater risks: if initiated further from menopause onset or in women aged 60 years and older
question
Duration of HRT Beer's Criteria
answer
Discontinue systemic HT in women aged 65 years and older is not supported by data
question
Decisions regarding whether to continue systemic HT is women aged older than 60 should be made on ....
answer
Individual basis - QOL - Persistent vasomotor symptoms - Prevention of bone loss and fracture
question
Early Menopause
answer
For women with POI or premature surgical menopause without contraindications, HT is recommended until at least the median age of menopause (52 y) Observational studies suggest that benefits outweigh the risks for effects on bone, heart, cognition, GSM, sexual function, and mood.
question
Observational evidence in FH of breast cancer
answer
Use of HT does not further alter the risk for breast cancer in women with a family history of breast cancer
question
Recommendations for women who are BRCA + w/o breast cancer
answer
Women who are BRCA-positive without breast cancer are at higher genetic risk of breast cancer, primarily ER-negative For those who have undergone surgical menopause (bilateral oophorectomy), benefits of estrogen to decrease health risks caused by premature loss of estrogen need to be considered. On the basis of limited observational studies, consider offering systemic HT until the median age of menopause (52 y). Discussions about longer use should be individualized.
question
Breast and endometrial cancer survivors: Treatment of bothersome GSM symptoms
answer
Low-dose vaginal ET used for the GSM has minimal systemic absorption (blood levels in the postmenopause range) and, on the basis of limited observational data, appears to hold minimal to no demonstrated risk for recurrence of endometrial or breast cancer
question
Women with early endometrial cancer who have completely successful treatment (including hysterectomy)
answer
Consideration may be given for low-dose vaginal ET for relief of GSM if nonhormone options are not successful, based on limited short-term safety trials.
question
Treatment in women who are survivors of breast cancer
answer
Decisions about low-dose vaginal ET should involve the woman's oncologist, particularly for women using AIs who have lowered overall estradiol levels.
question
What app does Dr Juengel care about?
answer
MenoPro AppBy the North American Menopause Society
question
Purpose of MenoPro
answer
Help clinicians and women/patients work together to personalize treatment decisions based on the patient's personal preferences
question
What are the 2 modes of MenoPro
answer
Health care provider Woman/patient
question
What does MenoPro provide?
answer
Information needed to determine each step - Lifestyle modifications - Contraindications/ precautions of HT Calculates CVD risk Gives list of products that are optional with doses Helps to determine what is best for patient based on characteristics
question
MenoPro Steps
answer
1. Asks Age 2. Asks if patient has Vasomotor Symptoms that impair QOL 3. Asks if patient has tried behavioral/lifestyle modifications for at least 3 months 4. Asks if patient is interested in considering HT and free of contraindications 5. Asks if woman is less than 10 years past onset of menopause 6. Asks if patient has had hysterectomy 7. Asks Patient's race/ethnicity 8. Asks if patient is current smoker 9. Asks if patient has been treated for high blood pressure 10. Asks systolic blood pressure 11. Asks if patient has diabetes 12. Asks if patient has cholesterol lowering medication 13. Asks total cholesterol level 14. Asks patient hdl
Get an explanation on any task
Get unstuck with the help of our AI assistant in seconds
New